Guanabenz
drug drugOn this page
Also known as GuanabenzoNSC-68982WY-8678SID26665151SID26751943SID90341577SID50104618SID50104619SID144204483CO-ADD:0136037guanabenGuanabenz acetateÊGuanabenz acetateÂGUANABEN-ACETATE
Summary
Guanabenz (CHEMBL420) is an approved small molecule targeting ADRA2A, ADRA2B, and ADRA2C; indicated across 2 conditions including relapsing-remitting multiple sclerosis and multiple sclerosis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Targets: 3 (ADRA2A, ADRA2B, ADRA2C)
- Indications: 2 conditions
- Clinical trials: 1
- Chemistry: 231.08 Da · C8H8Cl2N4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL420 |
| Name | Guanabenz |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 5702063 |
| Molecular formula | C8H8Cl2N4 |
| Molecular weight | 231.08 |
| InChIKey | WDZVGELJXXEGPV-YIXHJXPBSA-N |
SMILES: C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl
IUPAC name: 2-[(E)-(2,6-dichlorophenyl)methylideneamino]guanidine
Also known as: Guanabenz, Guanabenzo, NSC-68982, WY-8678, guanabenz, SID26665151, SID26751943, SID90341577, SID50104618, SID50104619, GUANABENZ, SID144204483
Parent form; salt/anhydrous children: CHEMBL1200560
Patent coverage: 4,306 distinct patent families (16,459 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| ADRA2A | α2A-adrenoceptor | Agonist | 7.7 | 0.1% | P08913 |
| ADRA2B | α2B-adrenoceptor | Agonist | 7.9 | 0.2% | P18089 |
| ADRA2C | α2C-adrenoceptor | Agonist | 6.4 | 0% | P18825 |
Broader ChEMBL bioactivity targets: 29 (assay-derived). Sample: Survival motor neuron protein, 4’-phosphopantetheinyl transferase ffp, 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Adrenergic receptor alpha-1, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Amine oxidase [flavin-containing] A, D(1A) dopamine receptor, Thromboxane A2 receptor, Adrenergic receptor alpha-2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, Alpha-1D adrenergic receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Mu-type opioid receptor.
Bioactivity
ChEMBL activities: 36 potent at pChembl ≥ 5 of 43 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P19328 | 8.77 | IC50 | 1.7 | nM | CHEMBL_ACT_150667 |
| ADRA2A | 8.09 | AC50 | 8.1 | nM | CHEMBL_ACT_25156406 |
| ADRA2A | 7.82 | Ki | 15 | nM | CHEMBL_ACT_7653664 |
| NISCH | 7.46 | Ki | 34.67 | nM | CHEMBL_ACT_2564074 |
| NISCH | 7.46 | Ki | 34.7 | nM | CHEMBL_ACT_2564075 |
| ADRA2A | 7.39 | IC50 | 41 | nM | CHEMBL_ACT_7653663 |
| ADRA1A | 7.37 | AC50 | 42.3 | nM | CHEMBL_ACT_25208507 |
| HTR2B | 7.21 | Ki | 62 | nM | CHEMBL_ACT_7657879 |
| ADRA2B | 7.17 | Ki | 68 | nM | CHEMBL_ACT_7653666 |
| TAAR1 | 7.05 | EC50 | 90 | nM | CHEMBL_ACT_16491743 |
| HTR2B | 7.01 | IC50 | 97 | nM | CHEMBL_ACT_7657878 |
| HTR2C | 6.97 | Ki | 107 | nM | CHEMBL_ACT_7657881 |
| HTR2A | 6.95 | Ki | 112 | nM | CHEMBL_ACT_7657877 |
| ADRA2B | 6.83 | IC50 | 149 | nM | CHEMBL_ACT_7653665 |
| P43140 | 6.8 | Ki | 158 | nM | CHEMBL_ACT_7653658 |
| ADRA2C | 6.79 | Ki | 161 | nM | CHEMBL_ACT_7653668 |
| HTR2C | 6.69 | IC50 | 204 | nM | CHEMBL_ACT_7657880 |
| ADRA1D | 6.63 | Ki | 232 | nM | CHEMBL_ACT_7653662 |
| P43140 | 6.41 | IC50 | 391 | nM | CHEMBL_ACT_7653657 |
| HTR2A | 6.41 | IC50 | 392 | nM | CHEMBL_ACT_7657876 |
| P15823 | 6.35 | IC50 | 450 | nM | CHEMBL_ACT_150666 |
| ADRA1D | 6.33 | IC50 | 472 | nM | CHEMBL_ACT_7653661 |
| HTR1A | 6.22 | AC50 | 603.8 | nM | CHEMBL_ACT_25165001 |
| P15823 | 6.12 | Ki | 755 | nM | CHEMBL_ACT_7653660 |
| ADRA2C | 5.96 | IC50 | 1106 | nM | CHEMBL_ACT_7653667 |
| TAAR1 | 5.93 | IC50 | 1173 | nM | CHEMBL_ACT_13128533 |
| P19327 | 5.93 | Ki | 1181 | nM | CHEMBL_ACT_7657873 |
| P15823 | 5.87 | IC50 | 1365 | nM | CHEMBL_ACT_7653659 |
| MAOA | 5.75 | IC50 | 1787 | nM | CHEMBL_ACT_7655797 |
| MTOR | 5.68 | Potency | 2075 | nM | CHEMBL_ACT_4522065 |
| P19327 | 5.68 | IC50 | 2068 | nM | CHEMBL_ACT_7657872 |
| MAOA | 5.49 | AC50 | 3206 | nM | CHEMBL_ACT_25160668 |
| SLC22A1 | 5.31 | IC50 | 4850 | nM | CHEMBL_ACT_18040337 |
| OPRM1 | 5.29 | AC50 | 5179 | nM | CHEMBL_ACT_25158152 |
| DRD1 | 5.1 | AC50 | 8026 | nM | CHEMBL_ACT_25115187 |
| SLC6A2 | 5.05 | AC50 | 8809 | nM | CHEMBL_ACT_25145977 |
Target pathways
Aggregated over 3 target gene(s): ADRA2A, ADRA2B, ADRA2C.
Top Reactome pathways
19 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Hemostasis | 3 | ADRA2A, ADRA2B, ADRA2C |
| Signal Transduction | 3 | ADRA2A, ADRA2B, ADRA2C |
| Signaling by GPCR | 3 | ADRA2A, ADRA2B, ADRA2C |
| Class A/1 (Rhodopsin-like receptors) | 3 | ADRA2A, ADRA2B, ADRA2C |
| Amine ligand-binding receptors | 3 | ADRA2A, ADRA2B, ADRA2C |
| GPCR downstream signalling | 3 | ADRA2A, ADRA2B, ADRA2C |
| Adrenoceptors | 3 | ADRA2A, ADRA2B, ADRA2C |
| Adrenaline signalling through Alpha-2 adrenergic receptor | 3 | ADRA2A, ADRA2B, ADRA2C |
| G alpha (i) signalling events | 3 | ADRA2A, ADRA2B, ADRA2C |
| G alpha (z) signalling events | 3 | ADRA2A, ADRA2B, ADRA2C |
| GPCR ligand binding | 3 | ADRA2A, ADRA2B, ADRA2C |
| Platelet activation, signaling and aggregation | 3 | ADRA2A, ADRA2B, ADRA2C |
| Platelet Aggregation (Plug Formation) | 3 | ADRA2A, ADRA2B, ADRA2C |
| Metabolism | 2 | ADRA2A, ADRA2C |
| Integration of energy metabolism | 2 | ADRA2A, ADRA2C |
| Metabolism of proteins | 2 | ADRA2A, ADRA2C |
| Adrenaline,noradrenaline inhibits insulin secretion | 2 | ADRA2A, ADRA2C |
| Regulation of insulin secretion | 2 | ADRA2A, ADRA2C |
| Surfactant metabolism | 2 | ADRA2A, ADRA2C |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| epidermal growth factor receptor signaling pathway | 3 |
| G protein-coupled receptor signaling pathway | 3 |
| negative regulation of norepinephrine secretion | 3 |
| regulation of vasoconstriction | 3 |
| platelet activation | 3 |
| negative regulation of epinephrine secretion | 3 |
| positive regulation of MAPK cascade | 3 |
| positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction | 3 |
| adrenergic receptor signaling pathway | 3 |
| adenylate cyclase-inhibiting adrenergic receptor signaling pathway | 3 |
| regulation of smooth muscle contraction | 3 |
| signal transduction | 3 |
| adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | 2 |
| female pregnancy | 2 |
| negative regulation of insulin secretion | 2 |
Indications & clinical
Indications
2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| relapsing-remitting multiple sclerosis | 1 | MONDO:0005314 | EFO:0003929 |
| multiple sclerosis | 1 | MONDO:0005301 | MONDO:0005301 |
Clinical trials
Total trials: 1.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02423083 | PHASE1 | TERMINATED | Oral Guanabenz for Multiple Sclerosis |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
607 molecules share ≥1 primary target. Top 100 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| ACLIDINIUM BROMIDE | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| Afatinib | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| Almotriptan | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CHENODIOL | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CLOZAPINE | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CRIZOTINIB | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| DESLORATADINE | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| DIHYDROERGOTAMINE | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| GENTIAN VIOLET | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| NAPHAZOLINE | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| OLANZAPINE | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| OLODATEROL | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| PALIPERIDONE | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| PRAMIPEXOLE | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| TAMSULOSIN | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| TEGASEROD | ChEMBL + PubChem | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| ACETOPHENAZINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| ALFUZOSIN | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| AMISULPRIDE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| AMITRIPTYLINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| AMOXAPINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| APOMORPHINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| APRACLONIDINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| ARIPIPRAZOLE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| ASENAPINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| AZELASTINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| BAZEDOXIFENE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| BENFLUOREX | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| BENPERIDOL | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| BENZBROMARONE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| BENZQUINAMIDE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| BENZTHIAZIDE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| BENZTROPINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| BITHIONOL | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| BREXPIPRAZOLE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| BRIMONIDINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| BROMOCRIPTINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| BROMPERIDOL | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CABERGOLINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CANDESARTAN CILEXETIL | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CARIPRAZINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CARVEDILOL | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CHLORHEXIDINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CHLOROQUINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CHLORPROMAZINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CINNARIZINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CISAPRIDE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CLEMASTINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CLOMIPRAMINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CLONIDINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| CYPROHEPTADINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| DANAZOL | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| DARIFENACIN | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| DEXMEDETOMIDINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| DIETHYLSTILBESTROL | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| DOBUTAMINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| DOMPERIDONE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| DOTHIEPIN | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| DOXAZOSIN | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| DOXEPIN | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| DROPERIDOL | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| EBASTINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| ECONAZOLE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| EPINEPHRINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| ERGOTAMINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| FLUPHENAZINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| GUANFACINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| HALOPERIDOL | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| HALOPROGIN | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| HYDROXYCHLOROQUINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| HYDROXYZINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| ILOPERIDONE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| INDORAMIN | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| IPRINDOLE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| KETOTIFEN | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| LABETALOL | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| LASOFOXIFENE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| LOFEXIDINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| LORCASERIN | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| LOXAPINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| LURASIDONE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| MAPROTILINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| MEBEVERINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| METHYLERGONOVINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| METHYSERGIDE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| MIANSERIN | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| MIRTAZAPINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| MOLINDONE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| MONTELUKAST | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| MOXISYLYTE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| MOXONIDINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| NAFTOPIDIL | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| NEBIVOLOL | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| NEFAZODONE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| NOREPINEPHRINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| NORTRIPTYLINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| OXICONAZOLE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
| OXYMETAZOLINE | ChEMBL | Phase 4 (approved) | ADRA2A, ADRA2B, ADRA2C |
Related Atlas pages
- Genes: ADRA2A, ADRA2B, ADRA2C
- Drugs: Aclidinium Bromide, Afatinib, Almotriptan, Chenodiol, Clozapine, Crizotinib, Desloratadine, Dihydroergotamine, Naphazoline, Olanzapine, Olodaterol, Paliperidone, Pramipexole, Tamsulosin, Tegaserod, Acetophenazine, Alfuzosin, Amisulpride, Amitriptyline, Amoxapine, Apomorphine, Apraclonidine, Aripiprazole, Asenapine, Astemizole, Azelastine, Bazedoxifene, Benfluorex, Benperidol, Benzbromarone, Benzquinamide, Benzthiazide, Benztropine, Bithionol, Brexpiprazole, Brimonidine, Bromocriptine, Bromperidol, Cabergoline, Candesartan Cilexetil, Cariprazine, Carvedilol, Chlorhexidine, Chloroquine, Chlorpromazine, Cinnarizine, Cisapride, Clemastine, Clomipramine, Clonidine, Clotrimazole, Cyproheptadine, Danazol, Darifenacin, Dexmedetomidine, Diethylstilbestrol, Dobutamine, Domperidone, Dothiepin, Doxazosin, Doxepin, Droperidol, Ebastine, Econazole, Epinephrine, Ergotamine, Fluphenazine, Guanfacine, Haloperidol, Haloprogin, Hydroxychloroquine, Hydroxyzine, Iloperidone, Indoramin, Iprindole, Ketotifen, Labetalol, Lasofoxifene, Lofexidine, Lorcaserin, Loxapine, Lurasidone, Maprotiline, Mebeverine, Methylergonovine, Methysergide, Mianserin, Mirtazapine, Molindone, Montelukast, Moxisylyte, Moxonidine, Naftopidil, Nebivolol, Nefazodone, Norepinephrine, Nortriptyline, Oxiconazole, Oxymetazoline